Natera (NTRA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of three Class II directors to serve until 2029 and one Class I director to serve until 2028.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve executive compensation as disclosed in the proxy statement.
Advisory vote on the frequency of future executive compensation votes.
Approval of an amendment to the 2015 Equity Incentive Plan.
Consideration of any other business that may properly come before the meeting.
Board of directors and corporate governance
Nominees for director positions include Rowan Chapman, Herm Rosenman, Jonathan Sheena (Class II), and Eric H. Rubin (Class I).
Executive compensation and say-on-pay
Advisory vote on the compensation of named executive officers.
Advisory vote on the frequency of future say-on-pay votes.
Proposal to amend the 2015 Equity Incentive Plan.
Latest events from Natera
- Q1 2026 revenue up 39% to $697M, record test volumes, raised guidance, but net loss widened.NTRA
Q1 20268 May 2026 - Proxy seeks approval for director elections, auditor, compensation, and equity plan amid strong growth.NTRA
Proxy filing23 Apr 2026 - Record Q4 revenue and margin gains, with strong 2026 growth and cash flow outlook.NTRA
Q4 20258 Apr 2026 - Signatera's growth accelerates with robust data, expanding coverage, and key FDA milestones ahead.NTRA
Leerink Global Healthcare Conference 202611 Mar 2026 - Record growth, expanding coverage, and aggressive R&D drive strong financial and market momentum.NTRA
47th Annual Raymond James Institutional Investor Conference5 Mar 2026 - Q2 revenue up 58% to $413.4M, gross margin 58.8%, guidance raised for FY2024.NTRA
Q2 20242 Feb 2026 - Strong Q2 growth, margin gains, and product innovation set up continued momentum into 2025.NTRA
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Strong Q1 growth, margin expansion, and clinical progress position the business for continued success.NTRA
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Innovation, clinical data, and commercial growth drive strong outlook across core health segments.NTRA
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026